MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Alpha-synuclein"

  • 2022 International Congress

    The overexpression of a-SYN leads to a differential process of mitophagy in neurons and atrocytes

    I. Lastres-Becker, S. Castro-Sánchez, I. Silva-Llanes, P. Teresak, JL. Lanciego, E. Sierra, P. Boya (Madrid, Spain)

    Objective: To determine the role of the different mitophagy pathways involved in PD, a key question that is still unresolved. We will investigate whether a-synuclein…
  • 2022 International Congress

    Early Synucleinopathy is Associated with Differential Regulation of Neurotransmission and Immune Related Genes

    J. Patterson, J. Kochmanski, A. Stoll, M. Kubik, C. Kemp, J. Howe, M. Duffy, K. Miller, A. Cole-Strauss, J. Beck, S. Counts, K. Steece-Collier, A. Bernstein, K. Luk, C. Sortwell (Grand Rapids, USA)

    Objective: Identification of gene expression changes in the rat substantia nigra pars compacta (SNpc) associated with early alpha-synuclein (a-syn) inclusion formation. Background: Accumulation of intracellular…
  • 2022 International Congress

    Evaluation of α-synuclein pathology and function in dopaminergic neurons derived from LRRK2 I1371V PD patient iPSCs

    I. Datta, S. Jagtap, C. Potdar (Bangalore, India)

    Objective: To evaluate cellular pathogenesis in DA neuron function, and α-synuclein pathology using LRRK2-I1371V PD iPSC. Background: It is reported for complex-neurodegenerative disorders like PD,…
  • 2022 International Congress

    A mouse model to test the cortical pathogenic theory of Parkinson’s disease

    M. Moreno-Gómez, D. Humanes-Valera, J. Pardo-Valencia, N. Mercado-García, B. Pro-Sánchez, A. Revuelto-González, T. Balzano, J. Blesa, A. Bortolozzi, J A. Obeso, G. Foffani (Móstoles, Spain)

    Objective: To develop a mouse model of chronic corticostriatal overactivity and increase expression of corticostriatal alpha-synuclein. Background: Parkinson’s disease typically has a focal motor onset1,…
  • 2022 International Congress

    The anti-alpha-synuclein antibody Lu AF82422 binds to pathological alpha-synuclein species from human brains and inhibits seeded alpha-synuclein aggregation

    P. Kallunki, K. Willén, F. Sotty, L. Buur, K. Bjerregaard-Andersen, M. Lubas, D. Damlund, M. Harndahl, K. Fog (Valby, Denmark)

    Objective: Lu AF82422 is a human IgG1 monoclonal antibody that binds all known forms of alpha-synuclein (aSyn), including monomeric, aggregated and truncated. Data are presented…
  • MDS Virtual Congress 2021

    Prasinezumab reduced progression of Parkinson’s disease motor features measured by Roche PD Mobile Application v2 sensor features: PASADENA Phase II Part 1

    K. Taylor, F. Lipsmeier, E. Volkova-Volkmar, D. Rukina, J. Anzures Cabrera, L. Essioux, M. Abt, B. van Lier, A. Thomann, H. Svoboda, W. Zago, R. Postuma, G. Pagano, M. Lindemann (Basel, Switzerland)

    Objective: To determine whether digital biomarker sensor data detect slowing in progression of core motor features of Parkinson’s disease (PD) in individuals with early PD…
  • MDS Virtual Congress 2021

    Dissociable contribution of serum NfL and p-tau181 to cognitive impairment and mild cognitive impairment in Parkinson’s disease.

    J. Pagonabarraga, R. Pérez-González, H. Bejr-Kasem, A. Horta-Barba, I. Aracil-Bolaños, S. Martinez-Horta, E. Rivas-Asensio, J. Perez-Perez, F. Sampedro, A. Campolongo, C. Izquierdo, B. Pascual-Sedano, J. Kulisevsky (Barcelona, Spain)

    Objective: To analyze the contribution of serum NfL and p-tau181 levels to cognitive impairment and mild cognitive impairment (PD-MCI) in non-demented PD patients. Background: Autopsy…
  • MDS Virtual Congress 2021

    GBA Mutation Accumulates Higher Alpha-Synuclein in Alpha-Synucleinopathies

    T. Eid (London, United Kingdom)

    Objective: To investigate whether post-translational modifications of α-synuclein will give rise to species that differ between PD cases with N370S GBA mutation and WT-PD. Background:…
  • MDS Virtual Congress 2021

    Quantitative systems pharmacology modelling of Parkinson’s disease to compare anti-α-synuclein therapeutics

    S. Bakshi, PH. Vander Graaf (Breda, Netherlands)

    Objective: We previously constructed a quantitative systems pharmacology (QSP) model of Parkinson’s disease (PD) that combines pathogenesis and spatial propagation of misfolded α-synuclein (Asyn) [1].…
  • MDS Virtual Congress 2021

    A new alpha-synuclein missense variant (Thr72Met) in two Turkish families with Parkinson’s disease

    C. Fevga, Y. Park, E. Lohmann, A J. Kievit, G J. Breedveld, F. Ferraro, L. de Boer, R. van Minkelen, H. Hanagasi, A. Boon, W. Wang, G A. Petsko, Q Q. Hoang, M. Emre, V. Bonifati (Rotterdam, Netherlands)

    Objective: To report the identification of a novel variant in the gene encoding alpha-synuclein (SNCA), segregating with Parkinson’s Disease (PD) in two families of Turkish…
  • « Previous Page
  • 1
  • …
  • 26
  • 27
  • 28
  • 29
  • 30
  • …
  • 60
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley